IL6 and Parkinson disease: By curtailing phosphorylated nuclear NFκB/p65 levels and obstructing the NF-κB/NLRP3 pathway, Astragaloside IV reduces NLRP3 and IL-1β concentrations, thus protecting dopaminergic neurons and reducing motor impairments.[157] Additionally, in SH-SY5Y cells from the PD model induced by 6-OHDA, Astragaloside IV inhibits the JAK2/STAT3 pathway, decreasing TNF-α, IL-6, and iNOS levels, which helps in mitigating neuroinflammation.[158]